Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy-Reference-Cited by-同舟云学术

Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy

Published:2022-11 Issue: Volume:Volume 14 Page:3191-3202
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Ge Wenzhen,Wu Ning,Jalbert Jessica J,Quek Ruben G W,Liu Jinjie,Rietschel Petra,Pouliot Jean-Francois,Harnett James,Hsu Melinda Laine,Feliciano Josephine L

Publisher

Informa UK Limited

Subject

Oncology

Reference26 articles.

1. National Comprehensive Cancer Network (NCCN). Non-small cell lung cancer. Version 3.2020; 2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed March 12, 2022.

2. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Updated version published 15 September 2020 by the ESMO guidelines committee; 2018. Available from: https://www.esmo.org/content/download/347819/6934778/1/ESMO-CPG-mNSCLC-15SEPT2020.pdf. Accessed March 12, 2022.

3. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

4. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

5. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of approaches to estimate real-world disease progression in lung cancer;JNCI Cancer Spectrum;2023-09-21